Summit Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Summit Therapeutics şirketinin toplam hissedar öz sermayesi $437.9M ve toplam borcu $24.5M olup, bu da borç-öz sermaye oranını 5.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $502.9M ve $64.9M dir.

Anahtar bilgiler

5.6%

Borç/özkaynak oranı

US$24.50m

Borç

Faiz karşılama oranı	n/a
Nakit	US$486.90m
Eşitlik	US$437.92m
Toplam yükümlülükler	US$64.93m
Toplam varlıklar	US$502.85m

Son finansal sağlık güncellemeleri

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SMMT 'nin kısa vadeli varlıkları ( $490.3M ) kısa vadeli yükümlülüklerini ( $59.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: SMMT şirketinin kısa vadeli varlıkları ( $490.3M ) uzun vadeli yükümlülüklerini ( $5.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SMMT şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: SMMT şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 5.6% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SMMT şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: SMMT serbest nakit akışı her yıl % 42.9 2.4 yıl yetecek nakit akışına sahip olacaktır.

Summit Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Summit Therapeutics Inc. Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Summit Therapeutics Inc. announced that it has received $234.945 million in funding

Summit Therapeutics Inc. Announces Data Relating to the HARMONi-2 Trial

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Summit Therapeutics May Have Further Upside From Here

Summit Therapeutics Inc. to Report Q2, 2024 Results on Aug 06, 2024

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Index

Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival

Summit Therapeutics Stock: Plunging Despite A Win?

Summit Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $90 million.

New major risk - Share price stability

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Summit Therapeutics Inc. to Report Q1, 2024 Results on May 01, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials

Summit Therapeutics Presents Research Data from Phase II Studies, Including Evidence Validating Microbiome Preservation, for Its Investigational Drug Ridinilazole

Summit Therapeutics to Present Research Updates At the 31St Annual ECCMID Conference, Including A Top-Rated ePoster

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator